MENU

3 Shares That Beat the Market Today

Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on changes – just in case they’re material to our investing thesis.

The Straits Times Index (SGX: ^STI) has managed to end the week on a slightly positive note as it inched up by 0.2% to 3,305 points today.

Given the STI’s small gains, let’s step outside the index to take a closer look at some market beaters which have made more notable gains.

Epicentre Holdings Limited (SGX: 5MQ) has closed at S$0.152 for an 8.6% gain after reaching an intra-day high of S$0.168. Today’s the launch of Apple Inc.’s iPhone 6 in Singapore. According to newswire The Straits Times, there were “hundreds” of people here queueing to get their hands on Apple’s latest smartphone.

Given that Epicentre’s a retailer of Apple products and other related paraphernalia, the company might experience some tailwinds in its business if there is persistently strong demand for Apple’s latest gadgets.

Fragrance Group Limited (SGX: F31) jumped by 6.7% to S$0.240 after announcing earlier today that it has plans to spin-off its property business in Australia to be listed on the Catalist stock exchange in Singapore.

This is an interesting move by Fragrance as it has only recently entered the Australian property market with the purchase of four plots of land (the acquisitions were made between May and July 2014) located in the central business districts of three different cities. These lands have a collective cost of A$167 million.

The spin-off is still “in its preliminary stages” and is dependent on a number of conditions which include regulatory approvals. As such, the company stressed that “there is no assurance that [the spin-off] will materialise in due course.”

QT Vascular Ltd (SGX: 5I0), which develops minimally invasive products for the treatment of complex vascular disease, rounds up the trio with its shares climbing by 4.1% to S$0.385. On Monday, the company revealed that it has enrolled its first European patients in the ENDURE trial in Germany. According to QT Vascular, “[m]ultiple patients have already been enrolled in this study with Dr. Andrew Holden, at Auckland City Hospital, in Auckland, New Zealand.”

The ENDURE trial is designed to evaluate the efficacy of one of QT Vascular’s products for a period of up to 12 months. The product in question is the Chocolate® Touch, a “novel drug-coated peripheral balloon” used for the treatment of patients with peripheral arterial disease.

Dr. Eitan Konstantino, Chief Executive Officer of QT Vascular, commented on the trial:

“We are very excited to expand the ENDURE trial in Europe and expect the enrolment to be faster with additional world class sites joining the study. It is very satisfying to see patients leaving the hospital without having to live with metal left in their leg for the rest of their life. I believe that this is where the field is trending and this is consistent with our vision. Chocolate® Touch represents a key milestone towards the commercialization of our second generation drug-coated balloons and will keep us competitive in the medical device market for peripheral artery diseases.”

To keep up to date on the latest financial and stock news, sign up now for a FREE subscription to The Motley Fool's weekly investing newsletter, Take Stock SingaporeIt will teach you how you can grow your wealth in the years ahead. Also, like us on Facebook to follow our latest hot articles.

The Motley Fool's purpose is to help the world invest, better.

The information provided is for general information purposes only and is not intended to be personalised investment or financial advice. Motley Fool Singapore writer Chong Ser Jing owns shares in Apple Inc.